Value through Innovation05 February 2016
24 September 2012

Recruitment complete for two pivotal Phase III studies of nintedanib* in patients with idiopathic pulmonary fibrosis

Ingelheim, Germany, 24 September 2012 – Boehringer Ingelheim is pleased to announce the last patients have been randomised into the Phase III sister trials assessing the efficacy and safety of nintedanib* (150 mg twice daily) in patients with idiopathic pulmonary fibrosis (IPF). The pivotal INPULSISTM Phase III trials continue as planned in study centres worldwide to assess the clinical outcomes in IPF patients treated with nintedanib*.

"Idiopathic pulmonary fibrosis is a severely debilitating condition which results in a progressive loss of lung function, associated with a clear deterioration in quality of life for our patients," said Luca Richeldi, MD, PhD, lead study author and director of the Research Centre for Rare Lung Diseases, University of Modena and Reggio Emilia, Modena, Italy. "As a treating physician I clearly see the high unmet need for effective new treatments which may substantially change the clinical course of this deadly disease. Modifying the decline in lung function or reducing the rate of acute exacerbations would clearly be crucially important goals."

Acute exacerbations are an unpredictable part of the clinical course of IPF, which can lead to death in one in two patients within a few months, and are in many ways different from exacerbations in other pulmonary disorders. Most importantly, in the absence of infections or alternative causes, patients experience acute worsening of dyspnoea, with evidence of new infiltrates on lung images.1 IPF is classified as a rare disease by the European Medicines Agency2 and the US National Institutes of Health3 with prevalence estimated to range from 14-43 per 100,000.4 Median survival is 2 to 3 years after diagnosis.1

Nintedanib* is an investigational small molecule tyrosine kinase inhibitor (TKI) which targets growth factor receptors, which have been shown to be potentially involved in pathomechanisms of pulmonary fibrosis, namely vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR) and platelet-derived growth factor receptor (PDGFR).5 The investigational compound received orphan-drug designation from the U.S. Food and Drug Administration in June 2011 and by the Ministry of Health, Labour and Welfare of Japan in September 2011.

Prof. Klaus Dugi, Corporate Senior Vice President Medicine, Boehringer Ingelheim

Prof. Klaus Dugi, Corporate Senior Vice President Medicine, Boehringer Ingelheim

"Boehringer Ingelheim is committed to research in areas of unmet medical need, regardless of how many patients are affected. We strive to improve the lives of patients with idiopathic pulmonary fibrosis," said Prof. Klaus Dugi, Corporate Senior Vice President Medicine, Boehringer Ingelheim. "Nintedanib* has shown promising results in a Phase II clinical trial and we are optimistic that the drug will further demonstrate its potential benefit in this devastating disease in the ongoing Phase III studies."

The primary endpoint of the two Phase III trials is the annual rate of decline in forced vital capacity (FVC) over a treatment period of 52 weeks in approximately 1,000 enrolled patients. Secondary endpoints include change from baseline in quality of life, time to first acute exacerbation, respiratory mortality, overall survival and on-treatment survival.6

The trials are being carried out in 23 countries in Europe, the Americas, Asia and Australia.

The Phase III trials aim to build upon the promising results of the Phase II TOMORROW trial, which demonstrated a positive trend in reducing lung function decline in IPF patients treated with 150 mg of nintedanib* twice daily when compared to placebo.7

About the Phase III sister trials (INPULSISTM-1 and INPULSISTM-2)
The two global sister Phase III clinical trials are double blind, randomised and placebo-controlled with a treatment duration of 52 weeks. The trials are evaluating the effect of oral nintedanib*, 150 mg twice daily, on annual rate of decline in Forced Vital Capacity (FVC), in patients with IPF. The trials have an identical design, matching dosing, inclusion criteria, and endpoints.6

The primary endpoint is the annual rate of decline in FVC (expressed in mL over 52 weeks). Among the secondary endpoints are: change from baseline in health-related quality of life, as assessed by the Saint-George’s Respiratory Questionnaire (SGRQ); time to first acute exacerbation (days); respiratory mortality; overall survival; on-treatment survival; time to death or lung transplant.6

Included were patients over 40 years of age with a diagnosis of IPF within five years before enrolment based on the most recent American Thoracic Society (ATS), European Respiratory Society (ERS), Japanese Respiratory Society (JRS), and Latin American Thoracic Association (ALAT) IPF guideline for diagnosis and management.6

The correct diagnosis was assessed by central reviewers based on a combination of high resolution computerised tomography pattern and surgical lung biopsy if available.6 More information can be found on (identifiers NCT01335464 and NCT01335477).

About nintedanib
Nintedanib* is an investigational small molecule tyrosine kinase inhibitor (TKI) in development by Boehringer Ingelheim for idiopathic pulmonary fibrosis (IPF).7 It targets growth factor receptors, which have been shown to be potentially involved in pathomechanisms of pulmonary fibrosis, most importantly the vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR) and platelet-derived growth factor receptor (PDGFR).5,7,8 By blocking these signaling pathways that are involved in fibrotic processes, it is believed that nintedanib* has the potential to reduce disease progression, slowing the decline of lung function.5,7 Nintedanib* is also in clinical development as a treatment option for cancer, including non-small cell lung cancer, ovarian cancer, colorectal cancer and hepatocellular carcinoma.7,9

About idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, severely debilitating and ultimately fatal lung disease for which there are only limited treatment options available to date.1 The incidence of IPF can vary considerably and there is some evidence that the patient population is increasing.10 IPF is characterised by progressive scarring of lung tissue and loss of lung function over time.1,11 Development of scarred tissue is called fibrosis.11 Over time, as the tissue thickens and stiffens with scarring, the lungs lose their ability to take in and transfer oxygen into the bloodstream, and vital organs do not get enough oxygen.11 As a result, individuals with IPF experience shortness of breath, cough and often have difficulty participating in everyday physical activities.12

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavours.

In 2011, Boehringer Ingelheim achieved net sales of about 13.2 billion euro. R&D expenditure in the business area Prescription Medicines corresponds to 23.5% of its net sales.

For more information please visit and, the new Boehringer Ingelheim resource for journalists with a special interest in respiratory research.

*Nintedanib is an investigational compound. Its safety and efficacy have not yet been fully established.


1Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824. 
2Orphanet. of diseases=Idiopathic-pulmonary-fibrosis&title=Idiopathic-pulmonary-fibrosis&search=Disease_Search_Simple EMA Accessed September 2012
3U.S. National Institutes of Health. Accessed September 2012
4Raghu G, Weycker D, Edelsberg J, et al. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006;174:810-6.
5Selman M, King TE, Pardo A, et al. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med. 2001;134(2):136-51.
6U.S. National Institutes of Health. Clinical Accessed September 2012
7Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365(12):1079-87.'
8Hilberg F, Roth GJ, Krssak M, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008; 68(12):4774-4782.
9 U.S. National Institutes of Health. BIBF 1120. Available at: Accessed September 2012.
10 Fernández Pérez E, Daniels C, Schroeder D, et al. Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study. Chest. 2010;137(1):129-37.
11 Pulmonary Fibrosis Foundation. What is IPF. 2011. Available at: Accessed September 2012.
12 Pulmonary Fibrosis Foundation. Symptoms. 2011. Available at: Accessed September 2012.

Media contact

  • Specht
    Boehringer Ingelheim

    Corporate Communications

    Dr Heike Specht
    Binger Strasse 173

    55216 Ingelheim